Table 4 Apoptotic and necrotic effects of IC50 of SOR-MIL-53 nanocomposite as analyzed by flow cytometry in the HepG2 cancer cell line after 24-hour treatment.

From: MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro

 

Untreated control

SOR/MOF

P-value

Viable cells

95.89% ± 11.25

18.49% ± 2.15*↓

0.0002

Necrosis

2.71% ± 0.17

36.79% ± 3.67*↑

0.0001

Late Apoptosis

0.13% ± 0.009

38.31% ± 2.5*↑

0.00001

Early Apoptosis

1.27% ± 0.011

6.41% ± 0.67*↑

0.0002

Back to article page